News

$SVM Declares Dividend – US$0.01 Semi-Annual, up from CAD $0.01

Trading Symbol: TSX/NYSE MKT: SVM

VANCOUVER, May 26, 2017  – Silvercorp Metals Inc. (“Silvercorp” or the “Company”) today announced that its Board of Directors declared a dividend of US$0.01 to be paid on or before June 30th, 2017 to shareholders of record at the close of business June 9th 2017

In November 2016, in light of improved operations, financial results, and a growing cash position the Company re-instated dividends, declaring a semi-annual dividend of CAD$0.01 per share (CAD$0.02 per share on an annual basis).  The Company has now decided to slightly increase the dividend by making the payment in U.S. funds rather than Canadian funds.

The dividends are considered eligible dividends for Canadian tax purposes.

The declaration and payment of future dividends is at the discretion of the Board of Directors and any future decision to pay dividends will be based on a number of factors including commodity prices, market conditions, financial results, cash flows from operations, expected cash requirements and other relevant factors.

About Silvercorp Metals Inc.

Silvercorp is a low-cost silver-producing Canadian mining company with multiple mines in China.   The Company’s vision is to deliver shareholder value by focusing on the acquisition of under developed projects with resource potential and the ability to grow organically.  For more information, please visit our website at www.silvercorpmetals.com

Friday, May 26th, 2017 News Comments Off

$AFSI Announces Closing of $300 Million Private Placement

NEW YORK, May 26, 2017  — AmTrust Financial Services, Inc. (Nasdaq:AFSI) (the “Company” or “AmTrust”) announced today that it has closed its previously announced private placement of 24,096,384 shares of common stock at a price of $12.45 per share, resulting in gross proceeds to the Company of US$300 million.

About AmTrust Financial Services, Inc.

AmTrust Financial Services, Inc., a multinational insurance holding company headquartered in New York City, offers specialty property and casualty insurance products, including workers’ compensation, commercial automobile, general liability and extended service and warranty coverage through its primary insurance subsidiaries rated “A” (Excellent) by A.M. Best. For more information about AmTrust visit www.amtrustgroup.com.

Forward-Looking Statements

This news release contains certain forward-looking statements that are intended to be covered by the safe harbors created by the Private Securities Litigation Reform Act of 1995. When we use words such as “anticipate,” “intend,” “plan,” “believe,” “estimate,” “expect,” or similar expressions, we do so to identify forward-looking statements. Examples of forward-looking statements include the plans and objectives of management for future operations, including those relating to future growth of our business activities and availability of funds, projections of the impact of potential errors or misstatements in our financial statements, and estimates of the impact of material weaknesses in our internal control over financial reporting, and are based on current expectations that involve assumptions that are difficult or impossible to predict accurately and many of which are beyond our control. Actual results may differ materially from those expressed or implied in these statements as a result of significant risks and uncertainties, including, but not limited to, non-receipt of expected payments from insureds or reinsurers, changes in interest rates, a downgrade in the financial strength ratings of our insurance subsidiaries, the effect of the performance of financial markets on our investment portfolio, the amounts, timing and prices of any share repurchases made by us under our share repurchase program, development of claims and the effect on loss reserves, accuracy in projecting loss reserves, the cost and availability of reinsurance coverage, the effects of emerging claim and coverage issues, changes in the demand for our products, our degree of success in integrating acquired businesses, the effect of general economic conditions, state and federal legislation, regulations and regulatory investigations into industry practices, the impact of known or potential errors or misstatements in our financial statements, our ability to timely and effectively remediate the material weaknesses in our internal control over financial reporting and implement effective internal control over financial reporting and disclosure controls and procedures in the future, risks associated with conducting business outside the United States, the impact of Brexit, developments relating to existing agreements, disruptions to our business relationships with Maiden Holdings, Ltd. or National General Holdings Corp., breaches in data security or other disruptions with our technology, heightened competition, changes in pricing environments, and changes in asset valuations. Additional information about these risks and uncertainties, as well as others that may cause actual results to differ materially from those projected, is contained in our filings with the SEC, including our Annual Report on Form 10-K and our quarterly reports on Form 10-Q. The projections and statements in this news release speak only as of the date of this release and we undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

For more information, please contact:

AmTrust Financial Services, Inc.
Chaya Cooperberg
Chief Communications Officer & SVP Corporate Affairs
chaya.cooperberg@amtrustgroup.com
646.458.3332
Friday, May 26th, 2017 News Comments Off

$SENS Announces Pricing of $41 Million Underwritten Offering of Common Stock

Senseonics Holdings, Inc. (NYSE-MKT:SENS), a medical technology company focused on the development and commercialization of Eversense®, a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the pricing of its underwritten offering of 29,078,014 shares of its common stock at a price of $1.41 per share to a group of institutional investors, including Roche Finance, Ltd., which has agreed to purchase 21,276,596 shares in the offering, and funds affiliated with New Enterprise Associates, which have agreed to purchase 7,092,198 shares in the offering. Gross proceeds to Senseonics from the offering are expected to be $41.0 million. The offering is expected to close on or about June 1, 2017, subject to customary closing conditions.

Leerink Partners LLC is acting as the sole book-running manager for the offering.

Senseonics intends to use the net proceeds from the offering to begin commercialization of Eversense in the United States, if approved, to fund continued research and development of future configurations of Eversense, and for working capital and general corporate purposes.

A shelf registration statement relating to the shares of common stock offered in the underwritten offering described above was filed with the Securities and Exchange Commission (SEC) on April 3, 2017 and declared effective by the SEC on April 17, 2017. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement and accompanying prospectus will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, telephone: (800) 808-7525, ext. 6132, email: syndicate@Leerink.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Senseonics Holdings, Inc.

Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics’ first generation CGM system, Eversense, includes a small sensor, smart transmitter and mobile application. Based on fluorescence sensing technology, the sensor is designed to be inserted subcutaneously and communicate with the smart transmitter to wirelessly transmit glucose levels to a mobile device. After insertion, the sensor is designed to continually and accurately measure glucose levels.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Senseonics Holdings, Inc., including statements about Senseonics’ the closing of the offering, anticipated use of proceeds and other statements containing the words “expect,” “intend,” “may,” “will,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the underwritten offering on the anticipated terms or at all, uncertainties inherent in the expanded commercial launch of Eversense and such other factors as are set forth in the risk factors detailed in Senseonics’ Annual Report on Form 10-K for the year ended December 31, 2016 and Senseonics’ other filings with the SEC under the heading “Risk Factors.” In addition, the forward-looking statements included in this press release represent Senseonics’ views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics’ views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics’ views as of any date subsequent to the date hereof.

 

Senseonics Holdings, Inc.
R. Don Elsey
Chief Financial Officer
301.556.1602
don.elsey@senseonics.com

Friday, May 26th, 2017 News Comments Off

$ECYT to Announce Updated Data on EC1456 and EC1169

WEST LAFAYETTE, Ind., May 26, 2017 — Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that two posters will be presented on its lead, clinical-stage assets, EC1456 and EC1169, at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 2 – 6, 2017, in Chicago.

Updated data will be presented on EC1456-01, a two part phase 1 dose escalation (Part A) and expansion (Part B) study. The presentation includes data for 87 Part A treated patients with advanced solid tumors and 6 Part B treated patients with FR-positive non-small cell lung cancer (NSCLC) as of the data cutoff on May 18, 2017. All patients were imaged to assess folate receptor expression with 99mTc-etarfolatide (FR expression not an eligibility criteria for Part A). Preliminary data from our first patient enrolled in the EC1456 ovarian surgical study, EC1456-02, will also be presented.

An update also will be provided for EC1169-01, a two-part phase 1 dose escalation (Part A) and expansion (Part B) study in patients with metastatic castration-resistant prostate cancer (mCRPC). The presentation includes data for the expansion phase (Part B) for 24 taxane-exposed mCRPC patients and 16 taxane-naïve mCRPC patients as of the data cutoff on May 15, 2017. All patients were imaged to assess PSMA expression with 99mTc-EC0652 (PSMA expression not an eligibility criteria).

The posters will be available on Endocyte’s website following presentation at the conference.

Presentations are as follows:

Abstract #: 2576
Title: Phase 1 dose escalation study of the folate receptor-targeted small molecule drug conjugate EC1456
Presenter: Dr. Wael Harb, Horizon Oncology Center
When: Monday, June 5, 8:00 a.m. – 11:30 a.m. CDT
Session Title: Poster Session: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Abstract #: 5038
Title: Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC)
Presenter: Dr. Michael Morris, Memorial Sloan Kettering Cancer Center
When: Monday, June 5, 1:15 p.m. – 4:45 p.m. CDT
Session Title: Poster Session: Genitourinary (Prostate) Cancer

 

About EC1456

EC1456 is an investigational therapeutic SMDC constructed of a high affinity FR-targeting ligand conjugated through a spacer and bioreleasable linker system to a potent cytotoxic microtubule inhibitor, tubulysin B hydrazide (TubBH). Patient FR-status is determined using the investigational companion imaging agent, etarfolatide. EC1456 is currently being evaluated in a phase 1 study in patients with advanced solid tumors (Part A) and FR-positive NSCLC (Part B) (ClinicalTrials.gov Identifier: NCT01999738) and a phase 1 exploratory study in patients with ovarian cancer undergoing surgery (ClinicalTrials.gov Identifier: NCT03011320).

About EC1169

EC1169 is an investigational therapeutic SMDC constructed of a high affinity prostate specific membrane antigen (PSMA)-targeting ligand conjugated through a bioreleasable linker system to a potent microtubule inhibitor, TubBH. Patient PSMA-status is determined using the investigational companion imaging agent, EC0652. EC1169 is currently being evaluated in a phase 1 study in patients with metastatic castration-resistant prostate cancer (mCRPC) (ClinicalTrials.gov Identifier: NCT02202447).

About Endocyte

Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases.  Endocyte uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging agents for personalized targeted therapies.  The company’s SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells.  This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone.  The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. For additional information, please visit Endocyte’s website at www.endocyte.com.

Endocyte Forward-Looking Statement

Certain of the statements made in this press release are forward looking, such as those relating to the company’s development programs and upcoming milestones. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks that the company may experience delays in the completion of its clinical trials (whether caused by competition, adverse events, patient enrollment rates, shortage of clinical trial materials, regulatory issues or other factors); risks that data from its clinical trials may not be indicative of subsequent clinical trial results; risks related to the safety and efficacy of the company’s product candidates; risks that early stage preclinical data may not be indicative of subsequent data when expanded to additional pre-clinical models or to subsequent clinical data; risks that evolving competitive activity and intellectual property landscape may impair the company’s ability to capture value for the technology; estimates of the potential markets for its product candidates; estimates of the capacity of manufacturing and other facilities required to support its product candidates; projected cash needs; and expected future revenues, operations, expenditures and cash position. More information about the risks and uncertainties faced by Endocyte, Inc. is contained in the company’s periodic reports filed with the Securities and Exchange Commission. Endocyte, Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

CONTACT: 
Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, stephanie@sternir.com
Friday, May 26th, 2017 News Comments Off

$CIIX Announces New Subsidiary Chinesehempoil.com, OptHemp Product Line

SAN GABRIEL, California, May 24, 2017  –

ChineseInvestors.com, Inc. (OTCQB: CIIX) (“CIIX” or the “Company”), the premier financial information website for Chinese-speaking investors, today announces that Chinesehempoil.com Inc., established last month as a wholly owned subsidiary of CIIX, will officially launch its own premium hemp health product line ‘OptHemp,’ which will include the Company’s first private label product, OptHemp Ultra Premium Hemp Oil.

The OptHemp products will be available at http://www.ChineseHempOil.com, the Company’s official bi-lingual site. CIIX will use multiple sales channels to implement its sales plan including online sales, retail sales and direct marketing. As part of its plan, CIIX is close to completing construction on its first retail store, which will be among the first retail stores to offer premium hemp-based products along with other health products in San Gabriel, CA. The Company is expected to open the retail store this June in an optimal location within one of the city’s premier Chinese consumer districts.

“I am very pleased to announce the launch of our first premium OptHemp product,” says Warren Wang, founder and CEO of CIIX. “Hemp oil is believed to have positive balancing effects on the mind and body of persons using them.”

OptHemp Ultra Premium Hemp Oil, the line’s base level product, is extracted and purified with raw materials from 100% organic farms in Colorado using a supercritical CO2 extraction technology. OptHemp products are GMO-free, making them attractive to consumers concerned about product source and purity.

“We believe that the desire for better quality of life in the Chinese community, coupled with fact that the aging population continues to grow, will lead to continued growth in the alternative health sector and increased demand for natural hemp-based health products,” says Wang. CIIX is confident that its OptHemp product line will lay a solid foundation for the Company’s entrance into the legal hemp industry and the alternative health sector.”

About ChineseInvestors.com (OTCQB: CIIX)

Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail and online sales of hemp-based products and other health related products.

For more information visit ChineseInvestors.com

Subscribe and watch our video commentaries: https://www.youtube.com/user/Chinesefncom

Follow us on Twitter for real-time Company updates: https://twitter.com/ChineseFNEnglsh

Like us on Facebook to receive live feeds: https://www.facebook.com/Chinesefncom

Add us on WeChat: Chinesefn or download iPhone iOS App: Chinesefn.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Contact:
ChineseInvestors.com, Inc.
227 W. Valley Blvd, #208 A
San Gabriel, CA 91776

Investor Relations:
Alan Klitenic
+1.214.636.2548

Corporate Communications:
NetworkNewsWire (NNW)
New York, New York
http://www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Wednesday, May 24th, 2017 News Comments Off

$KTNNF NetworkNewsWire Releases Exclusive Audio Interview with Kootenay Zinc

NEW YORK, NY–(Marketwired – May 24, 2017) – NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company that delivers a new generation of social communication solutions for business, today announces the online availability of its interview with Kootenay Zinc Corp. (OTCQB: KTNNF) (CSE: ZNK), a mineral exploration and development company focused on discovering large-scale sedimentary-exhalative (“SEDEX“) zinc deposits in Vancouver, British Columbia.

The interview can be heard at https://www.networknewswire.com/solutions/corporate-communications/interviews/kootenay-zinc-corp-interview/

Kicking off the interview, NNW’s Stuart Smith introduces Stuart (Tookie) Angus, a current independent business advisor to the mining industry and member of Kootenay Zinc’s advisory board, who provides a run-down of the company’s operations.

Kootenay Zinc is focused on the discovery of zinc ore body near the Sullivan Mine, which was previously one of the world’s largest zinc/lead/silver deposits. In operation for 100 years, the Sullivan Mine produced over $49 billion value of metal. Now, Kootenay Zinc hopes to replicate that success.

“We are about 30 kilometers, or 18 miles, from the mine, with a current drill program underway to try and discover [an extension] for the Sullivan Mine deposit,” says Angus.

Angus next provides insight into the potential of Kootenay Zinc’s mineral property, and notes that the company is adequately financed to carry-out its current drill program. He draws a parallel with the progress of Arizona Mining, a company drilling a large deposit of the same metals in Arizona, which recently carried out a private placement financing of $110 million.

“Going back to October of 2015, [Arizona Mining] was a micro-cap company trading at approximately $0.20 a share. Last week it carried out a private placement financing at a price of $2.45 per share, when the previous closing on the stock was $1.89… that $110 million financing was a huge endorsement of that project. So there you have a huge increase in terms of percentage and absolute value for a company that is still in the exploration phase, not yet in development. That’s the kind of target Kootenay Zinc is looking for,” says Angus.

Responsible for leading this charge is a well-qualified management team, including a “top-notch” geologist and geophysicist, which consistently updates shareholders on its progress and goals for 2017.

“We have a number of different anomalies that we’re going to test. The truth serum in this business is the drill bit. We’re going to go in there and bravely drill to see if we can find what we hope is there,” Angus says in conclusion.

About Kootenay Zinc Corp.

Kootenay Zinc Corp. is a mineral exploration and development company based in Vancouver, British Columbia that is presently targeting the Sully Property. The Company is focused on discovering large-scale sedimentary-exhalative (“SEDEX“) deposits.

The Sully Property comprises 1,375 hectares located approximately 30 kilometres (18 miles) east of Kimberley, B.C., and overlies rocks of similar age and origin as those which host the world-class Sullivan deposit, owned by Teck Resources Ltd. Sullivan was discovered in 1892, and is known to be one of the largest SEDEX deposits in the world. Over its 100-year lifetime, Sullivan produced approximately 150 million tonnes of ore, including approximately three hundred million ounces of silver, eight million tonnes of zinc and eight million tonnes of lead. The equivalent level of strata as at Sullivan and that formed on the margin of that same basin are present at the Sully Property. The Company cautions that past results or discoveries on proximate land are not necessarily indicative of the results that may be achieved on the Sully Property.

For more information visit www.kootenayzinc.com

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides to users (1) access to our news aggregation and syndication servers, (2) enhanced press release services, and (3) a full array of social communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Email Contact

Wednesday, May 24th, 2017 News Comments Off